Develops antibody medicines for cancer, inflammation and autoimmune disease, and licenses drug candidates to pharmaceutical partners.
10-K for FY2025, filed Mar 2, 2026Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel…View ↗
We seek to leverage our expertise in protein engineering and drug chemistry to discover and develop next-generation antibody-based…View ↗
Zanidatamab, our first internally developed product candidate to receive regulatory approval, illustrates the execution of this…View ↗
Pharmaceutical partners pay for licenses and technology access upfront, milestone payments when development or regulatory targets are met, and royalties tied to product sales; they also pay for research and development work as it is performed.
10-K for FY2025, filed Mar 2, 2026The Company has entered into a number of collaboration and licensing agreements. Promised deliverables within these agreements may include…View ↗
non-refundable, upfront license and platform technology access fees; research, development and regulatory milestone payments; research…View ↗
If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the…View ↗
At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company evaluates whether…View ↗
Research support, development and other paymentsView ↗
In addition, we could be eligible to receive future commercial milestones and increased royalties as additional indications of Ziihera are…View ↗
$106M
10-K for FY2025, filed Mar 2, 2026
$106M ↗
Pharmaceutical partners receive licenses to develop and commercialize drug candidates. BeOne handles zanidatamab commercial activity in Asia excluding Japan, Australia and New Zealand, while Jazz handles commercial activity in its territory; Zymeworks does not plan to market candidates itself.
10-K for FY2025, filed Mar 2, 2026
No. It lost $81.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
$173.7MView ↗
8-K, filed Nov 9, 2026
Royalty revenue from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne) was $2.3 million in the three months ended September 30, 2026…View ↗
8-K, filed Oct 23, 2026
On October 22, 2026, Zymeworks Inc. and its subsidiary Zymeworks BC Inc. (together, the “Company”) entered into a Collaboration and License…View ↗
8-K, filed Sep 23, 2026
Vancouver, British Columbia (September 23, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed…View ↗
8-K, filed Aug 25, 2026
Pursuant to the terms of the License and Collaboration Agreement, Zymeworks has earned a milestone payment of $250 million based on the FDA…View ↗
From drug developer to asset portfolio manager
The earlier report framed the business around discovering, developing and commercializing multifunctional biotherapeutics, led by a drug-candidate pipeline. The latest report centers on managing licensed assets and royalty streams through partnerships, while continuing internal research and development.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 2, 2026Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel…View ↗
Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and…View ↗
Through our asset and royalty aggregation strategy, we seek to optimize future cash flows from a growing portfolio of licensed products and…View ↗
Competes with F. Hoffmann-La Roche, Novartis Pharmaceuticals, Puma Biotechnology, AstraZeneca, Daiichi Sankyo, Seagen, MacroGenics, Jiangsu HengRui Medicine, Pfizer, Alphamab, BioNTech, Boehringer, Bayer, AbbVie, Genmab, Eli Lilly, Legend Biotech, Sotio, Akeso Bio, and Amgen
10-K for FY2025, filed Mar 2, 2026Zanidatamab is being developed for patients with solid tumors that express HER2, including patients with tumors expressing low levels of…View ↗
Loading...